Omecamtiv mecarbil, which has received a fast track designation from the US Food and Drug Administration, was developed for patients with heart failure with reduced ejection fraction. Meanwhile, aficamten is being tested for the potential treatment of hypertrophic cardiomyopathy.
The company said it will get the first $50 million upon closing, and the $250 million portion will be given in four tranches if certain milestones are achieved. Royalty Pharma will also pay up to $150 million in exchange for royalty on sales of aficamten.
Price: 38.98, Change: +0.2, Percent Change: +0.52